Peptide News
A static news aggregator refreshed from FDA MedWatch, PubMed, and ClinicalTrials.gov so the site can surface real signal without inventing headlines.
Latest sync: Sep 8, 2026, 6:34 AM. This page favors official and public primary sources over generic news scraping.
Display order is chronological from newest to oldest; future-dated or recently indexed items are pushed to the end.
Status: live
Status: live
Status: live
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates
This guidance describes the FDA’s regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA.
What moved most recently
Newly surfaced trials, FDA action, and PubMed additions sorted with the newest items first.
Newest peptide and GLP-1 updates
A rolling stream of the most recent official and public-source items in the tracker. Future-dated PubMed indexing artifacts stay at the bottom.
Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates
This guidance describes the FDA’s regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA.
Weight Loss Product Notifications
Learn about the warnings for weight loss products that contain hidden drugs and other hidden ingredients.
ZUBB Dietary Supplement may be harmful due to hidden ingredient
The Food and Drug Administration is advising consumers not to purchase or use ZUBB Dietary Supplement, a product promoted and sold for weight loss on various websites and possibly in some retail stores.
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Tirzepatide • RECRUITING • Eli Lilly and Company
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Tirzepatide • RECRUITING • Eli Lilly and Company
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Tirzepatide • COMPLETED • Novo Nordisk A/S
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Semaglutide • COMPLETED • Fundación para la Investigación del Hospital Clínico de Valencia
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Semaglutide • ACTIVE_NOT_RECRUITING • Novo Nordisk A/S
From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.
Curr Med Res Opin • Retatrutide • Journal Article
Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.
Appl Biochem Biotechnol • BPC-157 • Journal Article
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.
Pulmonology • Tirzepatide • Journal Article
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Retatrutide • ACTIVE_NOT_RECRUITING • Eli Lilly and Company
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
Curr Pain Headache Rep • BPC-157 • Journal Article
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Retatrutide • RECRUITING • Eli Lilly and Company
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Retatrutide • COMPLETED • Eli Lilly and Company
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
Int J Qual Stud Health Well-being • Semaglutide • Journal Article
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iScience • Retatrutide • Journal Article
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
J Enzyme Inhib Med Chem • Semaglutide • Journal Article
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Am J Sports Med • BPC-157 • Journal Article
GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.
Appetite • Semaglutide • Journal Article
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Appetite • Tirzepatide • Journal Article
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
J Chromatogr A • Retatrutide • Journal Article
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ Open • Tesamorelin • Journal Article
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Tesamorelin • RECRUITING • Massachusetts General Hospital
Body Composition and Adipose Tissue in HIV
Tesamorelin • TERMINATED • Columbia University
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Tesamorelin • RECRUITING • Hudson Biotech
FDA.gov
Regulatory and enforcement signal from FDA feeds that touch peptides, GLP-1s, compounding, and obesity.
ClinicalTrials.gov
Recently updated or newly visible clinical studies tied to tracked compounds and obesity-adjacent programs.
PubMed
Recent research hits for tracked peptide and GLP-1 terms, with reviews and meta-analyses surfaced when available.
This page is built from a generated JSON snapshot refreshed by scheduled syncs, not from a live browser request. FDA items come from RSS feeds, PubMed items come from NCBI utilities, and study updates come from the ClinicalTrials.gov API. The page is date-ordered for readability, while the underlying generator still scores relevance for homepage surfacing and future editorial modules.